The OCAv3 NGS assay offers a more time-, cost- and tissue-efficient method for simultaneously assessing POLE mutations and ERBB2 amplifications in uterine carcinomas, particularly in cases with limited tissue material. The gene discussed is POLE; the disease is uterine carcinoma.